Clearside Biomedical, Inc.
CLSD
$3.70
-$0.39-9.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 492.00K | 2.33M | 306.00K | 1.04M | 90.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 492.00K | 2.33M | 306.00K | 1.04M | 90.00K |
| Cost of Revenue | -- | 248.00K | 149.00K | -- | -- |
| Gross Profit | 492.00K | 2.08M | 157.00K | 1.04M | 90.00K |
| SG&A Expenses | 2.48M | 2.82M | 3.06M | 2.84M | 3.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.06M | 7.54M | 7.46M | 6.97M | 7.68M |
| Operating Income | -3.57M | -5.21M | -7.15M | -5.93M | -7.59M |
| Income Before Tax | -4.50M | -7.51M | -7.31M | -7.69M | -7.59M |
| Income Tax Expenses | -- | 715.00K | -- | -- | -- |
| Earnings from Continuing Operations | -4.50M | -8.22M | -7.31M | -7.69M | -7.59M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.50M | -8.22M | -7.31M | -7.69M | -7.59M |
| EBIT | -3.57M | -5.21M | -7.15M | -5.93M | -7.59M |
| EBITDA | -3.48M | -5.12M | -7.07M | -5.86M | -7.55M |
| EPS Basic | -0.87 | -1.60 | -1.44 | -1.54 | -1.52 |
| Normalized Basic EPS | -0.54 | -0.92 | -0.90 | -0.96 | -0.95 |
| EPS Diluted | -0.87 | -1.60 | -1.44 | -1.54 | -1.52 |
| Normalized Diluted EPS | -0.54 | -0.92 | -0.90 | -0.96 | -0.95 |
| Average Basic Shares Outstanding | 5.19M | 5.13M | 5.06M | 4.98M | 4.98M |
| Average Diluted Shares Outstanding | 5.19M | 5.13M | 5.06M | 4.98M | 4.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |